BRISTOL MYERS SQUIBB CO
CELG-RINext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for CELG-RI. That does not mean none is planned.
Get an email about CELG-RI's next catalysts
Track BRISTOL MYERS SQUIBB CO (CELG-RI) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
Opdivo
Renal Cell Carcinoma
Deucravacitinib
Psoriatic Arthritis
Relatlimab
Advanced Gastric Cancer
Cyclosporine A
Renal Transplant
BMS-986353
Systemic Sclerosis
Warfarin titrated to an INR of 2.5-3.0
Heart Failure
Glucovance (metformin HCl/glyburide)
Diabetes Mellitus, Non-Insulin-Dependent
ATV
HIV Infections
Atazanvir/ritonavir + efavirenz
HIV Infections
Atazanavir+ritonavir
HIV Infections
Belatacept
Renal Transplantation
SAR302503
Hematopoietic Neoplasm
Lenalidomide
Multiple Myeloma
Nelfinavir mesylate
HIV Infections
PEG-Interferon alfa 2a
Hepatitis C, Genotype 1
Double-blind Abatacept
Rheumatoid Arthritis
Tanespimycin
Advanced Malignancies
Atazanavir/Ritonavir
HIV
Brivanib
Hepato Cellular Carcinoma (HCC)
BMS-986278
Idiopathic Pulmonary Fibrosis
Sofosbuvir
Hepatitis C
BMS-986165
Psoriasis
KarXT
Alzheimer Disease
Sorivudine
HIV Infections
Daclatasvir
Hepatitis C Infection
KarX-EC
Alzheimer's Disease
Xanomeline/Trospium Chloride
Mania
Efavirenz
HIV Infections
Xanomeline Enteric Capsule
Alzheimer Disease
BMS-790052 (NS5A Replication Complex Inhibitor)
Hepatitis C
DCV 3DAA
Hepatitis C Virus Infection
Adefovir
Hepatitis B, Chronic
Cyclosporin A
Renal Transplantation
Atazanavir + ritonavir + tenofovir + nucleoside
HIV Infections
BMS-986504
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Luspatercept
Myelodysplastic Syndromes
Acetylsalicylic acid
Atrial Fibrillation
BMS-986205
Advanced Cancer
Epoetin Alfa
Myelodysplastic Syndromes
abatacept (ABA)
Ulcerative Colitis
pegIFNα-2b
Hepatitis C Virus Infection
Pumitamig
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Abatacept subcutaneous
Polymyositis
Ozanimod
Multiple Sclerosis, Relapsing-Remitting
Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
Rheumatoid Arthritis
Oral Azacitidine
Myelodysplastic Syndromes
Atazanavir (immediate switch)
HIV Infections
Abatacept plus
Myocarditis Acute
BMS-936558
Unresectable or Metastatic Melanoma
Dasatinib
Multiple Indications Cancer
Pegylated-Interferon-lambda
Hepatitis C Virus
Clopidogrel (SR25990)
Heart Defects, Congenital
Pemetrexed
Non-Small Cell Lung Cancer
Warfarin
Coronary Artery Bypass Grafting
Irbesartan monotherapy
Hypertension
Atazanavir
HIV Infections
Lamivudine/Zidovudine
HIV Infections
nab-Paclitaxel
Non-Small Cell Lung Cancer
Nab-paclitaxel/Paclitaxel
Breast Neoplasms
Videx EC
HIV Infections
Zidovudine (ZDV)
HIV Infections
Atazanavir Sulphate
HIV
Pomalidomide
Multiple Myeloma
Apremilast
Psoriatic Arthritis
Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)
Rheumatoid Arthritis
Tenofovir
Chronic Hepatitis B
Ribavirin
Hepatitis C
Aripiprazole oral product
Pervasive Developmental Disorder
Peg-interferon Alfa-2a
Hepatitis C Virus
Apixaban
Lymphoma
Iza-bren
Urothelial Cancer
Phenprocoumon
Atrial Fibrillation
Telaprevir
Hepatitis C
Abatacept SC
Sjögren's Syndrome
Aripiprazole 5mg
Major Depressive Disorder
Cyclosporine (CsA)
Kidney Transplantation
Xanomeline and Trospium Chloride Capsules
Schizophrenia
MDX-010 (anti-CTLA4) monoclonal antibody
Melanoma
Ixabepilone (Ixempra)
Breast Cancer
Paclitaxel and carboplatin
Carcinoma, Non-Small-Cell Lung
Pegylated interferon lambda (pegIFNλ)
Hepatitis C Virus (HCV)
Mavacamten
Cardiomyopathy, Hypertrophic
vinflunine
Transitional Cell Carcinoma
rHuPH20
Melanoma
Subcutaneous Abatacept
Rheumatoid Arthritis
Irbesartan
Atrial Fibrillation
stavudine, efavirenz, lamivudine
HIV Infections
pioglitazone hydrochloride
Type 2 Diabetes
current antiretroviral regimen
HIV Infection
ONO-4538
Non-Small Cell Lung Cancer
Abatacept
Rheumatoid Arthritis
emtricitabine, FTC (drug)
HIV Infections
Stavudine
HIV Infections
DCV/ASV/BMS-791325
Hepatitis C Virus
Subcutaneous (SC) Abatacept
Rheumatoid Arthritis (RA)
Muraglitazar
Metabolics Diabetes Nos
Apixaban 5 MG
Cancer-associated Thrombosis
Peginterferon Alfa-2a
Hepatitis C
clopidogrel (SR25990C)
Atrial Fibrillation
pexacerfont
Generalized Anxiety Disorder
Calcineurin inhibitor therapy
Failing Renal Allograft
Entecavir
Hepatitis B, Chronic
Elotuzumab
Multiple Myeloma
Atazanavir + Ritonavir
Human Immunodeficiency Virus (HIV) Infections
Didanosine
HIV Infections
FOLFOX
Colorectal Cancer
Bortezomib (B)
Multiple Myeloma
Asunaprevir (ASV)
Hepatitis C Virus
Asunaprevir
Hepatitis C
DCV
Hepatitis C
Bempegaldesleukin
Bladder Cancer
Lithium
Bipolar Disorder Type I With Mania
Enteric Coated Mycophenolate Sodium
Renal Allograft Recipients
Xanomeline/Trospium Chloride Capsule
Alzheimer Disease
Methotrexate (MTX)
Rheumatoid Arthritis (RA)
Irbesartan/HCTZ
Hypertension
Docetaxel/Paclitaxel
Esophageal Cancer
idecabtagene vicleucel
Multiple Myeloma
Iberdomide
Multiple Myeloma
Peginterferon Lambda-1a
Hepatitis C Virus (HCV)
atazanavir/ritonavir +2 NRTIs (immediate Switch Group)
HIV Infections
Topical Dapsone 5% Gel
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have
Atazanavir/ritonavir monotherapy
HIV-1 Infection
Mezigdomide
Relapsed or Refractory Multiple Myeloma
Atazanavir powder
HIV Infections
Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa
Breast Cancer
BMS-777607
Advanced Solid Tumors
Fedratinib
Primary Myelofibrosis
BMS-986231
Cardiac Failure
BMS-908662
Colorectal Cancer
BMS-770767
Diabetes Type 2
BMS-986507
Lung Cancer
BMS-986263
Hepatic Cirrhosis
INX-08189 50 mg QD X 5 days
Healthy
BMS-936557 (Anti-IP-10 Antibody)
Crohn's Disease
brivanib (active)
Hepatocellular Carcinoma (HCC)
MDX-010 (CTLA-4)
Melanoma
BMS-986207
Broad Solid Tumor
BMS-986517
Solid Tumours
Simeprevir
Hepatitis C Virus
CXCR1/2 Inhibitor SX-682
Metastatic Colon Adenocarcinoma
BMS-986489
Limited Stage Small Cell Lung Cancer
Carfilzomib
Multiple Myeloma
Dasatinib (BMS-354825)
Leukemia
APX005M
Cancer
DUAL
Cirrhosis
Oncovin
Peripheral T Cell Lymphoma
CRS-207
Previously Treated Metastatic Adenocarcinoma of the Pancreas
IPI-549 (eganelisib)
Bladder Cancer
Degarelix
Prostate Cancer
CC-486 300
Non-Small Cell Lung Cancer
lulizumab pegol
Living-Donor Kidney Transplant
ECF
Esophageal Cancer
lisocabtagene maraleucel
Lymphoma, Non-Hodgkin
Xanomeline and trospium chloride (KarXT)
SCHIZOPHRENIA 1 (Disorder)
pemetrexed disodium
Lung Cancer
Androgen Deprivation Therapy
Hormone Sensitive Prostate Cancer
Plinabulin
Lung Cancer
GM-CSF (Sargramostim)
Ovarian Cancer
Dasatinib Maximum Tolerated Dose
Non-Hodgkin's Lymphoma
Cetuximab,Paclitaxel, Carboplatin
Esophageal Cancer
UV1 vaccine + leukine
Cancer
CC-97540
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
HuMax-IL8
Head and Neck Squamous Cell Carcinoma
golcadomide
Follicular Lymphoma Stage II
xenon gas
Hypoxic Ischaemic Encephalopathy
BMS- 986205
Endometrial Adenocarcinoma
GVAX Pancreas Vaccine
Pancreatic Cancer
Bleomycin
Hodgkin Lymphoma
BMS-986249
Advanced Cancer
IDO1 Inhibitor BMS-986205
Lip
abatacept (Orencia ®)
Urticaria
Estramustine
Prostate Cancer
Fedratinib Pill
Myeloproliferative Neoplasm
pTVG-HP
Prostate Cancer
SipT Treatment
Prostate Cancer
Oral apixaban
Gynecologic Cancer
Vincristine Sulfate
Aggressive Non-Hodgkin Lymphoma
Drug Abilify
Depression
Neoantigen Dendritic Cell Vaccine
Hepatocellular Carcinoma
Pegylated Interferon alpha-2a
Hepatitis C Virus Genotype 4 Infection
Corticosteroid
Heart Transplantation
mFOLFIRINOX
Phase 2 Study
Chemotherapy, albumin-bound paclitaxel
Glioblastoma
Erbitux, Paclitaxel & Carboplatin
Cancer of Head and Neck
Corticosteroid: Betamethasone
Melanoma
Paclitaxel, vinorelbine, cisplatin
NSCLC Stage IIIB
pilimumab
Advanced Stage Non-small Cell Lung Cancer
roginolisib
Peripheral T Cells Lymphoma (PTCL)
Nulojix (Belatacept)
Renal Transplant
Clopidogrel 75 mg daily
Atherosclerosis
Testosterone cypionate
Castration-resistant Prostate Cancer
Dasatinib and Paclitaxel
Breast Cancer
TACE
Carcinoma, Hepatocellular
Low dose doxorubicin
Metastatic Breast Cancer
Tenofovir/emtricitabine
HIV Infections
gavo-cel
Mesothelioma
PD-1 blocking antibody
Nasopharyngeal Carcinoma
Varicella Zoster Vaccine
Herpes Zoster
Nevirapine
HIV Infections
Vinorelbine (Navelbine)
Non-small Cell Lung Cancer
ISA 101
Solid Tumors
BMS-754807
Breast Cancer
Aurexis®
Staphylococcus Aureus Bacteremia
Embolization Therapy
Metastatic Malignant Neoplasm in the Liver
Gemcitabine
Bladder Cancer
Chemotherapy (Cisplatin)
Non Small Cell Lung Cancer
Vitamin K Antagonist (VKA)
Thrombosis
CXL-1020
Heart Failure
KAI-9803
Myocardial Infarction
BMS-986528
Arthritis, Rheumatoid
Irinotecan + Carboplatin
Metastatic Breast Cancer
Platinum Doublet
Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
JNJ-70033093 25 mg
Arthroplasty, Replacement, Knee
Oral Taxane
Non-small Cell Lung Cancer
BMS-986253
Cancer
Vorolanib
Thymic Carcinoma
Temozolomide 50mg/m2/day
Adenocarcinoma - GEJ
BMS-986322
Psoriasis
Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a
HCV-HIV Co-Infection
BMS-986490
Advanced Solid Tumors
MYK-491
Heart Failure With Reduced Ejection Fraction
PSI-7977
Chronic Hepatitis C
200 mg INX-08189 Fasted
Hepatitis C
unfractionated heparin (UFH)
Antithrombotic
MORAb-202
Neoplasms, Ovarian
BMS-986523
Advanced Solid Malignancies
BMS-986259
Acute Decompensated Heart Failure
BMS-986036
Non-Alcoholic Steatohepatitis
BMS-823778
Dyslipidemia
Lirilumab
Non-Hodgkin's Lymphoma
MDX-1100
Rheumatoid Arthritis
Taxol
Breast Cancer
Interferon alfa-2b
Sarcoma, Kaposi
BMS-986213
Advanced Solid Tumors
Trametinib
Cancer
BMS-986158
Myelofibrosis
BMS-986020
Idiopathic Pulmonary Fibrosis
BMS-830216
Obesity
Strata 1 CXL-1020
Heart Failure
Enasidenib
T-cell Lymphoma
didanosine, ddI (drug)
HIV Infections
Enasidenib mesylat dose escalation
Leukemia
Radiotherapy
Carcinoma，Non-Small-Cell Lung
carboplatin + irinotecan
Neoplasms
BMS-986340
Cervical Cancer
BMS-986446
Alzheimer Disease, Early Onset
SAR302503 (TG101348)
Myelofibrosis
HNO Donor
Heart Failure
BMS-986435
Heart Failure
ixabepilone
Esophageal Cancer
BMS-790052
Hepatitis C Infection
BMS-986142
Rheumatoid Arthritis
CC-92480
Multiple Myeloma
Cabiralizumab
Advanced Pancreatic Cancer
CXL-1427
Heart Failure
Peginterferon α-2a
Hepatitis C
Tilsotolimod
Solid Tumor
CC-99282
Follicular Lymphoma
GVAX pancreatic cancer
Pancreatic Cancer
BMS-986156
Solid Tumors
MDX-010 / MDX-010 + Docetaxel
Prostate Cancer
CC-122
Melanoma
Salsalate
HIV
Iberdomide Hydrochloride
Smoldering Plasma Cell Myeloma
5-Fluorouracil (bolus)
Colorectal Cancer (CRC)
Cetuximab + Paclitaxel
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
atazanavir 300 mg + ritonavir 100 mg + dolutegravir 50 mg
HIV-1 Infection
Lamivudine
Hepatitis B Virus
BMS-986458
Relapsed/Refractory Non-Hodgkin Lymphoma
Thymoglobulin
Kidney Transplantation
BMS-690514
Non-Small-Cell Lung Carcinoma
Ritonavir
HIV Infections
Abatacept (BMS-188667)
Rheumatoid Arthritis
BMS-986288
Advanced Cancer
BMS-650032
Hepatitis C Virus
CC-486
Leukemia, Myeloid, Acute
BMS-986141
Thrombosis
Aurexis® (tefibazumab)
Staphylococcus Aureus
Cabazitaxel
Prostate Cancer
Pegylated Interferon Lambda
Hepatitis C
Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)
HIV Infections
BMS-986369
Relapsed or Refractory T-cell Lymphomas
5-fluorouracil (5-FU)
Colorectal Cancer
Peginterferon alpha-2a
Hepatitis C Infection
Exemestane + Dasatinib
Breast Cancer
Dasatinib 100 mg
Breast Cancer
MDX-010
Breast Cancer
BMS-986004 75 mg IV
Immune Thrombocytopenic Purpura
Vemurafenib
Melanoma
KOS-1584
Non-Small Cell Lung Cancer
INX-08189 50 mg
Healthy
Pegylated-interferon alfa-2a
Chronic Hepatitis C
BMS-708163
Alzheimer's Disease
BMS-954561
Diabetic Peripheral Neuropathic Pain
CCR2 Antagonist
Type 2 Diabetes
BMS-986012 (anti-fucosyl-GM1)
Small Cell Lung Cancer
BMS-986482
Advanced Solid Tumors
BMS-791325
Hepatitis C Virus
BMS-562086
Irritable Bowel Syndrome
Elotuzumab (BMS-901608)
Multiple Myeloma
BMS-986012
Extensive-stage Small Cell Lung Cancer
BMS-833923
Leukemia
BMS-986165 Dose A
Active Psoriatic Arthritis
BMS-986315
Advanced Solid Tumor
BMS-986470
Anemia, Sickle Cell
BMS-790052 (NS5A Inhibitor)
Hepatitis C
BMS-986525
Relapsed/Refractory Small Cell Lung Cancer
BMS-813160
Advanced Cancer
BMS-914392
Atrial Fibrillation
branebrutinib
Autoimmune Disorder
Megestrol acetate
Anorexia
BMS-582949
Vascular Diseases
Cobimetinib
Microsatellite Unstable Colorectal Cancer
Afimetoran
Systemic Lupus Erythematosus
BMS-820836
Depression
pegIFN
Hepatitis B Virus
Thalidomide
Relapsed and/or Refractory Multiple Myeloma
BMS-986449
Advanced Solid Tumors
Pegylated interferon alfa-2a
Hepatitis C Virus
Cyclosporine
Graft Rejection
Imzokitug
Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Anti-CD137 (4-1BB) (BMS-663513)
Melanoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Opdivo | Approved | Renal Cell Carcinoma | - | - |
Deucravacitinib | Phase 3 | Psoriatic Arthritis | - | - |
Relatlimab | Phase 3 | Advanced Gastric Cancer | - | - |
Cyclosporine A | Phase 3 | Renal Transplant | - | - |
BMS-986353 | Phase 3 | Systemic Sclerosis | - | - |
Warfarin titrated to an INR of 2.5-3.0 | Phase 3 | Heart Failure | - | - |
Glucovance (metformin HCl/glyburide) | Phase 3 | Diabetes Mellitus, Non-Insulin-Dependent | - | - |
ATV | Phase 3 | HIV Infections | - | - |
Atazanvir/ritonavir + efavirenz | Phase 3 | HIV Infections | - | - |
Atazanavir+ritonavir | Phase 3 | HIV Infections | - | - |
Belatacept | Phase 3 | Renal Transplantation | - | - |
SAR302503 | Phase 3 | Hematopoietic Neoplasm | - | - |
Lenalidomide | Phase 3 | Multiple Myeloma | - | - |
Nelfinavir mesylate | Phase 3 | HIV Infections | - | - |
PEG-Interferon alfa 2a | Phase 3 | Hepatitis C, Genotype 1 | - | - |
Double-blind Abatacept | Phase 3 | Rheumatoid Arthritis | - | - |
Tanespimycin | Phase 3 | Advanced Malignancies | - | - |
Atazanavir/Ritonavir | Phase 3 | HIV | - | - |
Brivanib | Phase 3 | Hepato Cellular Carcinoma (HCC) | - | - |
BMS-986278 | Phase 3 | Idiopathic Pulmonary Fibrosis | - | - |
Sofosbuvir | Phase 3 | Hepatitis C | - | - |
BMS-986165 | Phase 3 | Psoriasis | - | - |
KarXT | Phase 3 | Alzheimer Disease | - | - |
Sorivudine | Phase 3 | HIV Infections | - | - |
Daclatasvir | Phase 3 | Hepatitis C Infection | - | - |
KarX-EC | Phase 3 | Alzheimer's Disease | - | - |
Xanomeline/Trospium Chloride | Phase 3 | Mania | - | - |
Efavirenz | Phase 3 | HIV Infections | - | - |
Xanomeline Enteric Capsule | Phase 3 | Alzheimer Disease | - | - |
BMS-790052 (NS5A Replication Complex Inhibitor) | Phase 3 | Hepatitis C | - | - |
DCV 3DAA | Phase 3 | Hepatitis C Virus Infection | - | - |
Adefovir | Phase 3 | Hepatitis B, Chronic | - | - |
Cyclosporin A | Phase 3 | Renal Transplantation | - | - |
Atazanavir + ritonavir + tenofovir + nucleoside | Phase 3 | HIV Infections | - | - |
BMS-986504 | Phase 3 | Metastatic Non-small Cell Lung Cancer With MTAP Deletion | - | - |
Luspatercept | Phase 3 | Myelodysplastic Syndromes | - | - |
Acetylsalicylic acid | Phase 3 | Atrial Fibrillation | - | - |
BMS-986205 | Phase 3 | Advanced Cancer | - | - |
Epoetin Alfa | Phase 3 | Myelodysplastic Syndromes | - | - |
abatacept (ABA) | Phase 3 | Ulcerative Colitis | - | - |
pegIFNα-2b | Phase 3 | Hepatitis C Virus Infection | - | - |
Pumitamig | Phase 3 | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | - | - |
Abatacept subcutaneous | Phase 3 | Polymyositis | - | - |
Ozanimod | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | Phase 3 | Rheumatoid Arthritis | - | - |
Oral Azacitidine | Phase 3 | Myelodysplastic Syndromes | - | - |
Atazanavir (immediate switch) | Phase 3 | HIV Infections | - | - |
Abatacept plus | Phase 3 | Myocarditis Acute | - | - |
BMS-936558 | Phase 3 | Unresectable or Metastatic Melanoma | - | - |
Dasatinib | Phase 3 | Multiple Indications Cancer | - | - |
Pegylated-Interferon-lambda | Phase 3 | Hepatitis C Virus | - | - |
Clopidogrel (SR25990) | Phase 3 | Heart Defects, Congenital | - | - |
Pemetrexed | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Warfarin | Phase 3 | Coronary Artery Bypass Grafting | - | - |
Irbesartan monotherapy | Phase 3 | Hypertension | - | - |
Atazanavir | Phase 3 | HIV Infections | - | - |
Lamivudine/Zidovudine | Phase 3 | HIV Infections | - | - |
nab-Paclitaxel | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Nab-paclitaxel/Paclitaxel | Phase 3 | Breast Neoplasms | - | - |
Videx EC | Phase 3 | HIV Infections | - | - |
Zidovudine (ZDV) | Phase 3 | HIV Infections | - | - |
Atazanavir Sulphate | Phase 3 | HIV | - | - |
Pomalidomide | Phase 3 | Multiple Myeloma | - | - |
Apremilast | Phase 3 | Psoriatic Arthritis | - | - |
Abatacept (ABA) + Methotrexate (MTX), double-blind (DB) | Phase 3 | Rheumatoid Arthritis | - | - |
Tenofovir | Phase 3 | Chronic Hepatitis B | - | - |
Ribavirin | Phase 3 | Hepatitis C | - | - |
Aripiprazole oral product | Phase 3 | Pervasive Developmental Disorder | - | - |
Peg-interferon Alfa-2a | Phase 3 | Hepatitis C Virus | - | - |
Apixaban | Phase 3 | Lymphoma | - | - |
Iza-bren | Phase 3 | Urothelial Cancer | - | - |
Phenprocoumon | Phase 3 | Atrial Fibrillation | - | - |
Telaprevir | Phase 3 | Hepatitis C | - | - |
Abatacept SC | Phase 3 | Sjögren's Syndrome | - | - |
Aripiprazole 5mg | Phase 3 | Major Depressive Disorder | - | - |
Cyclosporine (CsA) | Phase 3 | Kidney Transplantation | - | - |
Xanomeline and Trospium Chloride Capsules | Phase 3 | Schizophrenia | - | - |
MDX-010 (anti-CTLA4) monoclonal antibody | Phase 3 | Melanoma | - | - |
Ixabepilone (Ixempra) | Phase 3 | Breast Cancer | - | - |
Paclitaxel and carboplatin | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Pegylated interferon lambda (pegIFNλ) | Phase 3 | Hepatitis C Virus (HCV) | - | - |
Mavacamten | Phase 3 | Cardiomyopathy, Hypertrophic | - | - |
vinflunine | Phase 3 | Transitional Cell Carcinoma | - | - |
rHuPH20 | Phase 3 | Melanoma | - | - |
Subcutaneous Abatacept | Phase 3 | Rheumatoid Arthritis | - | - |
Irbesartan | Phase 3 | Atrial Fibrillation | - | - |
stavudine, efavirenz, lamivudine | Phase 3 | HIV Infections | - | - |
pioglitazone hydrochloride | Phase 3 | Type 2 Diabetes | - | - |
current antiretroviral regimen | Phase 3 | HIV Infection | - | - |
ONO-4538 | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Abatacept | Phase 3 | Rheumatoid Arthritis | - | - |
emtricitabine, FTC (drug) | Phase 3 | HIV Infections | - | - |
Stavudine | Phase 3 | HIV Infections | - | - |
DCV/ASV/BMS-791325 | Phase 3 | Hepatitis C Virus | - | - |
Subcutaneous (SC) Abatacept | Phase 3 | Rheumatoid Arthritis (RA) | - | - |
Muraglitazar | Phase 3 | Metabolics Diabetes Nos | - | - |
Apixaban 5 MG | Phase 3 | Cancer-associated Thrombosis | - | - |
Peginterferon Alfa-2a | Phase 3 | Hepatitis C | - | - |
clopidogrel (SR25990C) | Phase 3 | Atrial Fibrillation | - | - |
pexacerfont | Phase 3 | Generalized Anxiety Disorder | - | - |
Calcineurin inhibitor therapy | Phase 3 | Failing Renal Allograft | - | - |
Entecavir | Phase 3 | Hepatitis B, Chronic | - | - |
Elotuzumab | Phase 3 | Multiple Myeloma | - | - |
Atazanavir + Ritonavir | Phase 3 | Human Immunodeficiency Virus (HIV) Infections | - | - |
Didanosine | Phase 3 | HIV Infections | - | - |
FOLFOX | Phase 3 | Colorectal Cancer | - | - |
Bortezomib (B) | Phase 3 | Multiple Myeloma | - | - |
Asunaprevir (ASV) | Phase 3 | Hepatitis C Virus | - | - |
Asunaprevir | Phase 3 | Hepatitis C | - | - |
DCV | Phase 3 | Hepatitis C | - | - |
Bempegaldesleukin | Phase 3 | Bladder Cancer | - | - |
Lithium | Phase 3 | Bipolar Disorder Type I With Mania | - | - |
Enteric Coated Mycophenolate Sodium | Phase 3 | Renal Allograft Recipients | - | - |
Xanomeline/Trospium Chloride Capsule | Phase 3 | Alzheimer Disease | - | - |
Methotrexate (MTX) | Phase 3 | Rheumatoid Arthritis (RA) | - | - |
Irbesartan/HCTZ | Phase 3 | Hypertension | - | - |
Docetaxel/Paclitaxel | Phase 3 | Esophageal Cancer | - | - |
idecabtagene vicleucel | Phase 3 | Multiple Myeloma | - | - |
Iberdomide | Phase 3 | Multiple Myeloma | - | - |
Peginterferon Lambda-1a | Phase 3 | Hepatitis C Virus (HCV) | - | - |
atazanavir/ritonavir +2 NRTIs (immediate Switch Group) | Phase 3 | HIV Infections | - | - |
Topical Dapsone 5% Gel | Phase 3 | Cetuximab-induced Papulopustular (Acneiform) Rash Who Have | - | - |
Atazanavir/ritonavir monotherapy | Phase 3 | HIV-1 Infection | - | - |
Mezigdomide | Phase 3 | Relapsed or Refractory Multiple Myeloma | - | - |
Atazanavir powder | Phase 3 | HIV Infections | - | - |
Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa | Phase 3 | Breast Cancer | - | - |
BMS-777607 | Phase 2 | Advanced Solid Tumors | - | - |
Fedratinib | Phase 2 | Primary Myelofibrosis | - | - |
BMS-986231 | Phase 2 | Cardiac Failure | - | - |
BMS-908662 | Phase 2 | Colorectal Cancer | - | - |
BMS-770767 | Phase 2 | Diabetes Type 2 | - | - |
BMS-986507 | Phase 2 | Lung Cancer | - | - |
BMS-986263 | Phase 2 | Hepatic Cirrhosis | - | - |
INX-08189 50 mg QD X 5 days | Phase 2 | Healthy | - | - |
BMS-936557 (Anti-IP-10 Antibody) | Phase 2 | Crohn's Disease | - | - |
brivanib (active) | Phase 2 | Hepatocellular Carcinoma (HCC) | - | - |
MDX-010 (CTLA-4) | Phase 2 | Melanoma | - | - |
BMS-986207 | Phase 2 | Broad Solid Tumor | - | - |
BMS-986517 | Phase 2 | Solid Tumours | - | - |
Simeprevir | Phase 2 | Hepatitis C Virus | - | - |
CXCR1/2 Inhibitor SX-682 | Phase 2 | Metastatic Colon Adenocarcinoma | - | - |
BMS-986489 | Phase 2 | Limited Stage Small Cell Lung Cancer | - | - |
Carfilzomib | Phase 2 | Multiple Myeloma | - | - |
Dasatinib (BMS-354825) | Phase 2 | Leukemia | - | - |
APX005M | Phase 2 | Cancer | - | - |
DUAL | Phase 2 | Cirrhosis | - | - |
Oncovin | Phase 2 | Peripheral T Cell Lymphoma | - | - |
CRS-207 | Phase 2 | Previously Treated Metastatic Adenocarcinoma of the Pancreas | - | - |
IPI-549 (eganelisib) | Phase 2 | Bladder Cancer | - | - |
Degarelix | Phase 2 | Prostate Cancer | - | - |
CC-486 300 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
lulizumab pegol | Phase 2 | Living-Donor Kidney Transplant | - | - |
ECF | Phase 2 | Esophageal Cancer | - | - |
lisocabtagene maraleucel | Phase 2 | Lymphoma, Non-Hodgkin | - | - |
Xanomeline and trospium chloride (KarXT) | Phase 2 | SCHIZOPHRENIA 1 (Disorder) | - | - |
pemetrexed disodium | Phase 2 | Lung Cancer | - | - |
Androgen Deprivation Therapy | Phase 2 | Hormone Sensitive Prostate Cancer | - | - |
Plinabulin | Phase 2 | Lung Cancer | - | - |
GM-CSF (Sargramostim) | Phase 2 | Ovarian Cancer | - | - |
Dasatinib Maximum Tolerated Dose | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
Cetuximab,Paclitaxel, Carboplatin | Phase 2 | Esophageal Cancer | - | - |
UV1 vaccine + leukine | Phase 2 | Cancer | - | - |
CC-97540 | Phase 2 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | - | - |
HuMax-IL8 | Phase 2 | Head and Neck Squamous Cell Carcinoma | - | - |
golcadomide | Phase 2 | Follicular Lymphoma Stage II | - | - |
xenon gas | Phase 2 | Hypoxic Ischaemic Encephalopathy | - | - |
BMS- 986205 | Phase 2 | Endometrial Adenocarcinoma | - | - |
GVAX Pancreas Vaccine | Phase 2 | Pancreatic Cancer | - | - |
Bleomycin | Phase 2 | Hodgkin Lymphoma | - | - |
BMS-986249 | Phase 2 | Advanced Cancer | - | - |
IDO1 Inhibitor BMS-986205 | Phase 2 | Lip | - | - |
abatacept (Orencia ®) | Phase 2 | Urticaria | - | - |
Estramustine | Phase 2 | Prostate Cancer | - | - |
Fedratinib Pill | Phase 2 | Myeloproliferative Neoplasm | - | - |
pTVG-HP | Phase 2 | Prostate Cancer | - | - |
SipT Treatment | Phase 2 | Prostate Cancer | - | - |
Oral apixaban | Phase 2 | Gynecologic Cancer | - | - |
Vincristine Sulfate | Phase 2 | Aggressive Non-Hodgkin Lymphoma | - | - |
Drug Abilify | Phase 2 | Depression | - | - |
Neoantigen Dendritic Cell Vaccine | Phase 2 | Hepatocellular Carcinoma | - | - |
Pegylated Interferon alpha-2a | Phase 2 | Hepatitis C Virus Genotype 4 Infection | - | - |
Corticosteroid | Phase 2 | Heart Transplantation | - | - |
mFOLFIRINOX | Phase 2 | Phase 2 Study | - | - |
Chemotherapy, albumin-bound paclitaxel | Phase 2 | Glioblastoma | - | - |
Erbitux, Paclitaxel & Carboplatin | Phase 2 | Cancer of Head and Neck | - | - |
Corticosteroid: Betamethasone | Phase 2 | Melanoma | - | - |
Paclitaxel, vinorelbine, cisplatin | Phase 2 | NSCLC Stage IIIB | - | - |
pilimumab | Phase 2 | Advanced Stage Non-small Cell Lung Cancer | - | - |
roginolisib | Phase 2 | Peripheral T Cells Lymphoma (PTCL) | - | - |
Nulojix (Belatacept) | Phase 2 | Renal Transplant | - | - |
Clopidogrel 75 mg daily | Phase 2 | Atherosclerosis | - | - |
Testosterone cypionate | Phase 2 | Castration-resistant Prostate Cancer | - | - |
Dasatinib and Paclitaxel | Phase 2 | Breast Cancer | - | - |
TACE | Phase 2 | Carcinoma, Hepatocellular | - | - |
Low dose doxorubicin | Phase 2 | Metastatic Breast Cancer | - | - |
Tenofovir/emtricitabine | Phase 2 | HIV Infections | - | - |
gavo-cel | Phase 2 | Mesothelioma | - | - |
PD-1 blocking antibody | Phase 2 | Nasopharyngeal Carcinoma | - | - |
Varicella Zoster Vaccine | Phase 2 | Herpes Zoster | - | - |
Nevirapine | Phase 2 | HIV Infections | - | Patent 2029 |
Vinorelbine (Navelbine) | Phase 2 | Non-small Cell Lung Cancer | - | - |
ISA 101 | Phase 2 | Solid Tumors | - | - |
BMS-754807 | Phase 2 | Breast Cancer | - | - |
Aurexis® | Phase 2 | Staphylococcus Aureus Bacteremia | - | - |
Embolization Therapy | Phase 2 | Metastatic Malignant Neoplasm in the Liver | - | - |
Gemcitabine | Phase 2 | Bladder Cancer | - | - |
Chemotherapy (Cisplatin) | Phase 2 | Non Small Cell Lung Cancer | - | - |
Vitamin K Antagonist (VKA) | Phase 2 | Thrombosis | - | - |
CXL-1020 | Phase 2 | Heart Failure | - | - |
KAI-9803 | Phase 2 | Myocardial Infarction | - | - |
BMS-986528 | Phase 2 | Arthritis, Rheumatoid | - | - |
Irinotecan + Carboplatin | Phase 2 | Metastatic Breast Cancer | - | - |
Platinum Doublet | Phase 2 | Resectable Stage IIA to IIIB Non-small Cell Lung Cancer | - | - |
JNJ-70033093 25 mg | Phase 2 | Arthroplasty, Replacement, Knee | - | - |
Oral Taxane | Phase 2 | Non-small Cell Lung Cancer | - | - |
BMS-986253 | Phase 2 | Cancer | - | - |
Vorolanib | Phase 2 | Thymic Carcinoma | - | - |
Temozolomide 50mg/m2/day | Phase 2 | Adenocarcinoma - GEJ | - | - |
BMS-986322 | Phase 2 | Psoriasis | - | - |
Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a | Phase 2 | HCV-HIV Co-Infection | - | - |
BMS-986490 | Phase 2 | Advanced Solid Tumors | - | - |
MYK-491 | Phase 2 | Heart Failure With Reduced Ejection Fraction | - | - |
PSI-7977 | Phase 2 | Chronic Hepatitis C | - | - |
200 mg INX-08189 Fasted | Phase 2 | Hepatitis C | - | - |
unfractionated heparin (UFH) | Phase 2 | Antithrombotic | - | - |
MORAb-202 | Phase 2 | Neoplasms, Ovarian | - | - |
BMS-986523 | Phase 2 | Advanced Solid Malignancies | - | - |
BMS-986259 | Phase 2 | Acute Decompensated Heart Failure | - | - |
BMS-986036 | Phase 2 | Non-Alcoholic Steatohepatitis | - | - |
BMS-823778 | Phase 2 | Dyslipidemia | - | - |
Lirilumab | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
MDX-1100 | Phase 2 | Rheumatoid Arthritis | - | - |
Taxol | Phase 2 | Breast Cancer | - | - |
Interferon alfa-2b | Phase 2 | Sarcoma, Kaposi | - | - |
BMS-986213 | Phase 2 | Advanced Solid Tumors | - | - |
Trametinib | Phase 2 | Cancer | - | - |
BMS-986158 | Phase 2 | Myelofibrosis | - | - |
BMS-986020 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
BMS-830216 | Phase 2 | Obesity | - | - |
Strata 1 CXL-1020 | Phase 2 | Heart Failure | - | - |
Enasidenib | Phase 2 | T-cell Lymphoma | - | - |
didanosine, ddI (drug) | Phase 2 | HIV Infections | - | - |
Enasidenib mesylat dose escalation | Phase 2 | Leukemia | - | - |
Radiotherapy | Phase 2 | Carcinoma，Non-Small-Cell Lung | - | - |
carboplatin + irinotecan | Phase 2 | Neoplasms | - | - |
BMS-986340 | Phase 2 | Cervical Cancer | - | - |
BMS-986446 | Phase 2 | Alzheimer Disease, Early Onset | - | - |
SAR302503 (TG101348) | Phase 2 | Myelofibrosis | - | - |
HNO Donor | Phase 2 | Heart Failure | - | - |
BMS-986435 | Phase 2 | Heart Failure | - | - |
ixabepilone | Phase 2 | Esophageal Cancer | - | - |
BMS-790052 | Phase 2 | Hepatitis C Infection | - | - |
BMS-986142 | Phase 2 | Rheumatoid Arthritis | - | - |
CC-92480 | Phase 2 | Multiple Myeloma | - | - |
Cabiralizumab | Phase 2 | Advanced Pancreatic Cancer | - | - |
CXL-1427 | Phase 2 | Heart Failure | - | - |
Peginterferon α-2a | Phase 2 | Hepatitis C | - | - |
Tilsotolimod | Phase 2 | Solid Tumor | - | - |
CC-99282 | Phase 2 | Follicular Lymphoma | - | - |
GVAX pancreatic cancer | Phase 2 | Pancreatic Cancer | - | - |
BMS-986156 | Phase 2 | Solid Tumors | - | - |
MDX-010 / MDX-010 + Docetaxel | Phase 2 | Prostate Cancer | - | - |
CC-122 | Phase 2 | Melanoma | - | - |
Salsalate | Phase 2 | HIV | - | - |
Iberdomide Hydrochloride | Phase 2 | Smoldering Plasma Cell Myeloma | - | - |
5-Fluorouracil (bolus) | Phase 2 | Colorectal Cancer (CRC) | - | - |
Cetuximab + Paclitaxel | Phase 2 | Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | - | - |
atazanavir 300 mg + ritonavir 100 mg + dolutegravir 50 mg | Phase 2 | HIV-1 Infection | - | - |
Lamivudine | Phase 2 | Hepatitis B Virus | - | - |
BMS-986458 | Phase 2 | Relapsed/Refractory Non-Hodgkin Lymphoma | - | - |
Thymoglobulin | Phase 2 | Kidney Transplantation | - | - |
BMS-690514 | Phase 2 | Non-Small-Cell Lung Carcinoma | - | - |
Ritonavir | Phase 2 | HIV Infections | - | - |
Abatacept (BMS-188667) | Phase 2 | Rheumatoid Arthritis | - | - |
BMS-986288 | Phase 2 | Advanced Cancer | - | - |
BMS-650032 | Phase 2 | Hepatitis C Virus | - | - |
CC-486 | Phase 2 | Leukemia, Myeloid, Acute | - | - |
BMS-986141 | Phase 2 | Thrombosis | - | - |
Aurexis® (tefibazumab) | Phase 2 | Staphylococcus Aureus | - | - |
Cabazitaxel | Phase 2 | Prostate Cancer | - | - |
Pegylated Interferon Lambda | Phase 2 | Hepatitis C | - | - |
Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC) | Phase 2 | HIV Infections | - | - |
BMS-986369 | Phase 2 | Relapsed or Refractory T-cell Lymphomas | - | - |
5-fluorouracil (5-FU) | Phase 2 | Colorectal Cancer | - | - |
Peginterferon alpha-2a | Phase 2 | Hepatitis C Infection | - | - |
Exemestane + Dasatinib | Phase 2 | Breast Cancer | - | - |
Dasatinib 100 mg | Phase 2 | Breast Cancer | - | - |
MDX-010 | Phase 2 | Breast Cancer | - | - |
BMS-986004 75 mg IV | Phase 2 | Immune Thrombocytopenic Purpura | - | - |
Vemurafenib | Phase 2 | Melanoma | - | - |
KOS-1584 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
INX-08189 50 mg | Phase 2 | Healthy | - | - |
Pegylated-interferon alfa-2a | Phase 2 | Chronic Hepatitis C | - | - |
BMS-708163 | Phase 2 | Alzheimer's Disease | - | - |
BMS-954561 | Phase 2 | Diabetic Peripheral Neuropathic Pain | - | - |
CCR2 Antagonist | Phase 2 | Type 2 Diabetes | - | - |
BMS-986012 (anti-fucosyl-GM1) | Phase 2 | Small Cell Lung Cancer | - | - |
BMS-986482 | Phase 2 | Advanced Solid Tumors | - | - |
BMS-791325 | Phase 2 | Hepatitis C Virus | - | - |
BMS-562086 | Phase 2 | Irritable Bowel Syndrome | - | - |
Elotuzumab (BMS-901608) | Phase 2 | Multiple Myeloma | - | - |
BMS-986012 | Phase 2 | Extensive-stage Small Cell Lung Cancer | - | - |
BMS-833923 | Phase 2 | Leukemia | - | - |
BMS-986165 Dose A | Phase 2 | Active Psoriatic Arthritis | - | - |
BMS-986315 | Phase 2 | Advanced Solid Tumor | - | - |
BMS-986470 | Phase 2 | Anemia, Sickle Cell | - | - |
BMS-790052 (NS5A Inhibitor) | Phase 2 | Hepatitis C | - | - |
BMS-986525 | Phase 2 | Relapsed/Refractory Small Cell Lung Cancer | - | - |
BMS-813160 | Phase 2 | Advanced Cancer | - | - |
BMS-914392 | Phase 2 | Atrial Fibrillation | - | - |
branebrutinib | Phase 2 | Autoimmune Disorder | - | - |
Megestrol acetate | Phase 2 | Anorexia | - | - |
BMS-582949 | Phase 2 | Vascular Diseases | - | - |
Cobimetinib | Phase 2 | Microsatellite Unstable Colorectal Cancer | - | - |
Afimetoran | Phase 2 | Systemic Lupus Erythematosus | - | - |
BMS-820836 | Phase 2 | Depression | - | - |
pegIFN | Phase 2 | Hepatitis B Virus | - | - |
Thalidomide | Phase 2 | Relapsed and/or Refractory Multiple Myeloma | - | - |
BMS-986449 | Phase 2 | Advanced Solid Tumors | - | - |
Pegylated interferon alfa-2a | Phase 2 | Hepatitis C Virus | - | - |
Cyclosporine | Phase 2 | Graft Rejection | - | - |
Imzokitug | Phase 2 | Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | - | - |
Anti-CD137 (4-1BB) (BMS-663513) | Phase 2 | Melanoma | - | - |
Advanced Cancer
1 drug in this indication
Advanced melanoma with progression on anti-PD-1 therapy
1 drug in this indication
pediatric indication
1 drug in this indication
Non-small Cell Lung Cancer
1 drug in this indication
HIV Infections
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in BRISTOL MYERS SQUIBB CO's drug pipeline?→
CatalystAlert tracks 323 drug candidates in BRISTOL MYERS SQUIBB CO's (CELG-RI) pipeline across Phase 3, Phase 2, Approved. Its lead program is Opdivo (Approved). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BRISTOL MYERS SQUIBB CO's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for BRISTOL MYERS SQUIBB CO (CELG-RI) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CELG-RI biotech catalysts?→
Add CELG-RI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BRISTOL MYERS SQUIBB CO's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.